Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Edge Restenosis with Everolimus Eluting Stents: a few Predictors

Edge Restenosis with Everolimus Eluting StentsStent edge restenosis continues to be a weakness of drug eluting stents (DES). The aim of this study was to determine its predictors using optical coherence tomography (OCT).

 

The study retrospectively analyzed 319 patients receiving OCT immediately after everolimus eluting stent implantation (EES) looking into the immediate outcome, and follow up angiography at 9 and 12 months.

 

Binary angiographic stent edge restenosis was 10%. OCT more often showed lipidic plaque in patients with stent edge restenosis vs. those without it. (61% vs. 20%; p<0.001), as well as smaller minimal lumen area (4.13±2.61 vs. 5.58±2.46 mm2; p=0.001). Multivariable analysis confirmed these two variables are significant predictors of stent edge restenosis.

 

A lipidic arc of 185° (sensitivity: 71%; specificity: 72%; area under the curve: 0.761) and minimal lumen area of 4.10 mm2 (sensitivity: 67%; specificity: 77%; area under the curve: 0.787) were the ideal cutoff values to predict stent edge restenosis.

 

These results do not come as a surprise since it is well known that plaque in the distal or proximal stent edges and stent underexpansion are restenosis predictors.

 

Conclusion

OCT provides decisive information on optimal stent diameter and expansion to select the right stent length, which in turn will allow us to cover the whole plaque.

 

Original Title: Optical Coherence Tomography Predictors for Edge Restenosis after Everolimus-Eluting Stent Implantation.

Reference: Ino Y et al. Circ Cardiovasc Interv. 2016 Oct; 9(10).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...